James R Howe
Overview
Explore the profile of James R Howe including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
172
Citations
3908
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Mouser B, Howe J, Atari O, Dillon J, Chandrasekharan C, Parekh K, et al.
Int J Cardiol Cardiovasc Risk Prev
. 2024 Jun;
22:200293.
PMID: 38911359
Background: Screening for carcinoid heart disease (CHD), has historically lacked consensus expert guidelines. In 2017, the North American Neuroendocrine Tumor Society (NANETS) released expert recommendations for CHD screening among NET...
12.
Chang J, Sherman S, De Andrade J, Hoshi H, Howe J, Chan C
J Surg Res
. 2024 Apr;
298:269-276.
PMID: 38636183
Introduction: Despite improvements in preoperative image resolution, approximately 10% of curative-intent resection attempts for pancreatic ductal adenocarcinoma are aborted at the time of operation. To avoid nontherapeutic laparotomy, many surgeons...
13.
Dunton K, Hedrick N, Meamardoost S, Ren C, Howe J, Wang J, et al.
J Neurosci
. 2024 Jan;
44(10).
PMID: 38238073
Experience-dependent gene expression reshapes neural circuits, permitting the learning of knowledge and skills. Most learning involves repetitive experiences during which neurons undergo multiple stages of functional and structural plasticity. Currently,...
14.
Pietan L, Vaughn H, Howe J, Bellizzi A, Smith B, Darbro B, et al.
Int J Mol Sci
. 2023 Dec;
24(24).
PMID: 38139230
Determining neuroendocrine tumor (NET) primary sites is pivotal for patient care as pancreatic NETs (pNETs) and small bowel NETs (sbNETs) have distinct treatment approaches. The diagnostic power and prioritization of...
15.
Fath M, Liu D, Ewald J, Robles-Planells C, Tomanek-Chalkley A, Graves S, et al.
Radiat Res
. 2023 Nov;
201(1):35-47.
PMID: 37989124
Intermediate to high-grade lung neuroendocrine tumors (NETs; i.e., atypical carcinoid tumors) and neuroendocrine carcinomas (NECs) are currently difficult to cure. These tumors were found to express the CXCR4 G-protein coupled...
16.
Postel M, Darabi S, Howe J, Liang W, Craig D, Demeure M
F1000Res
. 2023 Nov;
12:417.
PMID: 37954063
Small bowel carcinoids are insidious tumors that are often metastatic when diagnosed. Limited mutation landscape studies of carcinoids indicate that these tumors have a relatively low mutational burden. The development...
17.
Tow D, Chan C, Howe J, Ear P
Surgery
. 2023 Nov;
175(3):726-734.
PMID: 37914574
Background: Serotonin is emerging as a promising therapeutic target in tryptophan hydroxylase 1-positive tumors, but further mechanistic studies are needed to effectively target dysregulated serotonin metabolism. One challenge is a...
18.
Beyer G, Hueser S, Li R, Manika D, Lee M, Chan C, et al.
Surgery
. 2023 Nov;
175(3):605-612.
PMID: 37914572
Background: Gastroenteropancreatic neuroendocrine carcinomas are rare neoplasms with no effective treatments and poor prognosis. Few reliable preclinical models exist for the study of gastroenteropancreatic neuroendocrine carcinomas, limiting investigation of novel...
19.
Del Rivero J, Perez K, Kennedy E, Mittra E, Vijayvergia N, Arshad J, et al.
J Clin Oncol
. 2023 Sep;
41(32):5049-5067.
PMID: 37774329
Purpose: To develop recommendations for systemic therapy for well-differentiated grade 1 (G1) to grade 3 (G3) metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Methods: ASCO convened an Expert Panel to conduct a...
20.